Latest news, press releases, and SEC filings for CervoMed Inc (CRVO) https://caymanjournal.com/stock/CRVO en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Mon, 27 Apr 2026 22:53:41 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 📄 What This Document Is 📰 This filing is a press release announcing significant new scientific data presented by CervoMed Inc. (NASDAQ: CRVO) at the 2026 AAN Annual Meeting in Chicago. This document details the results from the RewinD-LB Phase 2b clinical trial, focusing on the drug neflamapimod https://caymanjournal.com/stock/CRVO/sec-filing/0001437749-26-013037 https://caymanjournal.com/stock/CRVO/sec-filing/0001437749-26-013037 Wed, 22 Apr 2026 00:00:00 GMT SEC Filing # 📢 What This Document Is This is an 8-K filing, which is like a company's official "news flash" to the stock market. CervoMed is using it to announce that it will be presenting major updates about its key drug, neflamapimod, at important medical conferences. It's a way to build credibility and sha https://caymanjournal.com/stock/CRVO/sec-filing/0001437749-26-011597 https://caymanjournal.com/stock/CRVO/sec-filing/0001437749-26-011597 Tue, 07 Apr 2026 00:00:00 GMT SEC Filing